Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089829 | 0.83 | GSK3B (0.46) | GSK3BIDO1PARP10PARP11CYP19A1 | |
| SCHEMBL497227 | 0.83 | GSK3B (0.52) | GSK3BCDC7ROCK2MAP4K4HIPK2 | |
| Hydrochloric Acid SCHEMBL3819113 | 0.81 | GSK3B (0.51) | GSK3BCDC7ROCK2MAP4K4HIPK2 | |
| SCHEMBL82630 | 0.75 | RXFP1 (0.40) | GSK3B | |
| SCHEMBL698310 | 0.74 | MAPT (0.42) | GSK3B | |
| SCHEMBL101767 | 0.73 | GSK3B (0.60) | GSK3B | |
| SCHEMBL23458980 | 0.70 | SMN1; SMN2 (0.42) | CYP19A1 | |
| SCHEMBL2683964 | 0.70 | IDO1 (0.45) | GSK3BIDO1PARP10PARP11CYP19A1 | |
| SCHEMBL12948696 | 0.70 | PARP10 (0.38) | GSK3BIDO1PARP10PARP11CYP19A1 | |
| SCHEMBL4084455 | 0.70 | IDO1 (0.42) | GSK3BIDO1PARP10PARP11CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129377-B2 | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-2261224-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101048397-A | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI PHARMA CORP (JP) | 2007-10-03 | — | — | CN | disclosed |
| EP-1805164-A2 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006036015-A2 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, PSEN1 | GSK3B 89/4885IDO1 1637/4885PARP10 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.